Insider Buying: Repligen Co. (NASDAQ:RGEN) Director Acquires 250 Shares of Stock

Repligen Co. (NASDAQ:RGEN - Get Free Report) Director Margaret Pax purchased 250 shares of the business's stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Repligen Trading Up 0.5 %

Shares of RGEN traded up $0.68 during mid-day trading on Friday, reaching $140.02. The company's stock had a trading volume of 623,142 shares, compared to its average volume of 650,573. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $200.03. The company's fifty day moving average price is $156.18 and its two-hundred day moving average price is $148.32. The stock has a market cap of $7.86 billion, a PE ratio of -274.55, a P/E/G ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. On average, analysts predict that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Remove Ads

Analyst Ratings Changes

Several brokerages have commented on RGEN. HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Canaccord Genuity Group began coverage on Repligen in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price for the company. JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. TD Cowen began coverage on Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 target price for the company. Finally, Royal Bank of Canada raised their target price on Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $178.64.

Institutional Investors Weigh In On Repligen

Large investors have recently added to or reduced their stakes in the company. Signaturefd LLC grew its holdings in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new stake in Repligen in the 4th quarter worth $29,000. Raiffeisen Bank International AG bought a new stake in Repligen in the 4th quarter worth $29,000. Resources Management Corp CT ADV bought a new stake in Repligen in the 3rd quarter worth $37,000. Finally, Quarry LP boosted its stake in shares of Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 239 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.